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Forkhead Box F1 promotes breast cancer
cell migration by upregulating lysyl oxidase
and suppressing Smad2/3 signaling
Gisela Nilsson1,2 and Marie Kannius-Janson2*
Abstract
Background: Epithelial-mesenchymal transition (EMT) increases cell migration and is implicated in cancer cell
invasion and metastasis. We have previously described the involvement of the transcription factors, nuclear factor
I-C2 (NFI-C2) and Forkhead box F1 (FoxF1), in the regulation of EMT and invasion during breast tumor progression.
NFI-C2 counteracts these processes and FoxF1 is a directly repressed target of NFI-C2. FoxF1 induces EMT and
invasiveness and enhances xenograft tumorigenicity in nude mice. Here we identify oppositely regulated targets
of NFI-C2 and FoxF1 involved in these processes and further study a possible role for FoxF1 in tumorigenesis.
Methods: We used Affymetrix microarray to detect changes in the transcriptome of a mouse mammary epithelial
cell line upon overexpression of NFI-C2 or FoxF1. To elucidate the effects and signaling events following FoxF1
overexpression we investigated in vitro invasion capacity and changes in transcription and protein expression
resulting from RNAi and inhibitor treatment.
Results: The extracellular matrix enzyme lysyl oxidase (LOX) was negatively regulated by NFI-C2 and positively
regulated by FoxF1, and upregulation of LOX following FoxF1 overexpression in mouse mammary epithelial cells
increased in vitro cell invasion. In the nuclei of FoxF1-overexpressing cells, the phosphorylation of Smad2 decreased,
while that of p38 increased. Depletion of LOX by RNAi enhanced phosphorylation of Smad2 by a focal adhesion kinase
(FAK)-dependent mechanism. In addition, induced expression of FoxF1 in a non-malignant human mammary epithelial
cell line showed that the increase in LOX transcription and the suppression of Smad2 activity are early effects of FoxF1.
Conclusion: These data show that FoxF1 enhances invasion in a LOX-dependent manner, is involved in the
regulation of Smad2 signaling, and that FoxF1 overexpression ultimately leads to activation of p38 MAPK signaling.
These findings provide new insights into the regulation of signaling pathways known to be important during breast
tumor progression.
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Background
During epithelial-mesenchymal transition (EMT), epithe-
lial cells lose their epithelial characteristics and acquire a
mesenchymal phenotype. EMT is important during devel-
opment, but also implicated in carcinoma cell progression
and invasion and may contribute to the advancement of
breast carcinoma to metastasis [1, 2].
We have previously described a role for the transcrip-
tion factor Nuclear factor I-C2 (NFI-C2) in breast tumor
development where NFI-C2 prevents EMT, motility, in-
vasiveness and tumor growth [3]. NFI-C2 is lost during
breast tumor progression and is virtually absent from
lymph node metastases. Patients classified as stage II in-
vasive breast cancer with NFI-C2 in their breast tumor
cells have better prognosis compared to those without
detectable NFI-C2 [3]. In mammary epithelial cells, the
amount of active NFI-C2 is regulated by prolactin, via
Janus activated kinase 2 localized in the nucleus [4].
NFI-C2 is known to activate p53 and to participate in
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the regulation of expression of milk genes during preg-
nancy [5, 6]. We also identified a direct transcriptional
repression by NFI-C2 of the transcription factor Fork-
head box F1 (FoxF1). This finding provides a possible
mechanism through which NFI-C2 inhibits EMT, since
FoxF1 was shown to induce EMT and invasiveness, and
forced expression of FoxF1 enhanced xenograft tumori-
genesis in nude mice [3]. This was the first demonstra-
tion of a role of FoxF1 in cancer. Previously known
functions of FoxF1 includes activities in mesenchymal
cells during development and importance for mesoderm
differentiation, vasculogenesis and organogenesis [7–10].
FoxF1 also promotes mesenchymal cell migration by
transcriptionally regulating integrin β3 [11] and plays an
important role in tumor stromal cells by stimulating
cancer cell migration [12].
Lysyl oxidase (LOX) is an extracellular matrix enzyme
that catalyzes the cross-linking of collagens or elastin,
thereby controlling the structure and tensile strength of
the extracellular matrix. LOX is synthesized as a 48 kDa
precursor, N-glycosylated and secreted as a 50 kDa pro-
enzyme. In the extracellular compartment, pro-LOX is
processed to the 32 kDa catalytically active LOX and an
18 kDa pro-peptide. LOX belongs to a gene family con-
sisting of five members; LOX, LOX-like 1 (LOXL1),
LOXL2, LOXL3 and LOXL4. All play important roles in
regulating extracellular matrix remodeling and homeosta-
sis. Recently, novel roles of LOX have been demonstrated
including the ability to regulate gene transcription [13],
cell differentiation and tissue development [14], and cell
adhesion, motility and migration [15–17]. This implicates
a role for LOX during tumor progression. For example,
LOX has been shown to have critical roles in EMTand in-
vasiveness [18]. LOX-mediated collagen crosslinking can
also promote tumor progression and invasion by increas-
ing extracellular matrix stiffness [19]. Elevated LOX levels
in breast cancer positively correlate with invasiveness and
reduced metastasis-free and overall survival [20, 21].
Here we show that LOX is downregulated by NFI-C2
and upregulated by FoxF1 and that FoxF1-mediated up-
regulation of LOX is responsible for the invasiveness
caused by FoxF1 overexpression. Further, we show that




Total RNA was prepared from three pools of NF1-C2S-,
FoxF1-, or vector control expressing HC11 cells (GenElute
Mammalian total RNA kit; Sigma-Aldrich, Stockholm,
Sweden). RNA integrity was verified by electrophoresis on
a bio-analyzer (model 2100; Agilent, Palo Alto, CA). Five
micrograms of each RNA preparation was labeled and hy-
bridized to a Mouse Gene ST 1.0 Array. Hybridization
and scanning of the arrays were performed at SCIBLU
Microarray Resource Centre (MARC; Lund, Sweden).
Antibodies
LOX (Novus Biologicals, NB100-2527), FoxF1 (Human
Protein Atlas project, HPA003454 (mAb FoxF1 3454)),
FAK-pY576 and FAK (Invitrogen), FAK-pY396 (Santa Cruz),
α-tubulin (Sigma), Smad2-pSer465–467 (Calbiochem), Smad2/
3 (Cell Signaling), p38-pT180-Y182 and p38 (Cell signaling),
HDAC-1 (Santa Cruz), p130Cas-pY249 and p130Cas (Cell
signaling).
Cell culture
The mouse mammary epithelial cell line HC11 was
grown in RPMI 1640 supplemented with 10 % FCS, 1 %
PEST, 5 μg/mL insulin and 10 μg/mL EGF. The human
mammary epithelial cell line HB2 was grown in DMEM
supplemented with 10 % FCS, 1 % PEST, 10 μg/mL insu-
lin and 5 μg/mL hydrocortisone. Transfectants carrying
the tetracycline repressor construct had 10 μg/mL blasti-
cidin S and transfectants additionally carrying IRES-GFP
constructs also had 0,5 μg/mL Geneticin added to the
medium. Cells were grown at 37 °C and 5 % CO2.
Revers transcription PCR analysis
Total RNA was extracted from cells using Sigma-
Aldrich GenElute Mammalian Total RNA Miniprep kit.
Reverse transcription PCR was performed with Titan One
Tube RT-PCR System kit from Roche Applied Science.
Reverse transcription-quantitative PCR analysis
cDNA was synthesized using a QuantiTect Reverse
Transcription Kit (Qiagen) according to manufacturer’s
instructions. Real-time PCR (RT-PCR) was performed
using Qiagen kit for SYBR® Green-based real-time PCR
and were run on a LightCycler 480 (Roche, Sweden).
The following primers were used: Mm FoxF1; −5′ACAT
CAAGCAACAGCCTCTGTC3′- and −5′ATGTCTTGG
TAGGTGACCTC3′-, Mm LOX; QT00098028 (Qiagen),
Hs FoxF1; QT00029687 (Qiagen), Hs LOX: −5′CCACT
ATGACCTGCTTGATG3′- and −5′CATACGCATGATG
TCCTGTG3′-. Melting curve analysis was performed to
ensure that only one PCR product had been produced. A
standard curve was generated for quantification and for
estimating amplification efficiency using increasing con-
centrations of cDNA, and the amplification transcripts
were quantified with the relative standard curve and nor-
malized to the GAPDH reference gene.
RNA interference
Two 20-nucleotide small interfering RNA (siRNA) du-
plexes targeting LOX was used; GGCTGAAGGCCAC
AAAGCAA (Dharmacon), used in Fig. 3. Transfection was
carried out using oligofectamine (Invitrogen) according to
Nilsson and Kannius-Janson BMC Cancer  (2016) 16:142 Page 2 of 12
manufacturer’s instructions. And, CUGGCGCCAGACAA
UCCAAUU (Dharmacon), used in Additional file 1:
Figure S3. Transfection was carried out using HiPerfect
(Qiagen) according to manufacturer’s instructions. A 21-
nucleotide siRNA duplex was used for targeting p130Cas
(QIAGEN). The sequence was CAGGAGGTGTCTCGT
CCAATA. Transfection of siRNA duplex was carried out
using oligofectamine (Invitrogen) according to manufac-
turer’s instructions.
Invasion assay
Invasion assays were performed using BD BioCoat Matrigel
Invasion chambers with 8-mm pore size according to
the manufacturer’s instructions (VWR International).
After 48 h incubation, top cells were removed and bottom
cells were counted.
Protein preparations
For whole-cell extract preparation, cells were treated
with lysis buffer (150 mM NaCl, 50 mM Tris–HCl
[pH 8], 1 % Triton X-100, 1 mM Na3VO4, 10 mM NaF
and 1× Complete (Roche)) for 30 min at 4 °C. Prepara-
tions of nuclear extracts were made as described by
Ausubel, F et al. 1987. Protein concentrations of the ex-
tracts were determined by using BioRad Protein Assay.
Western blot
The different extracts were electrophoresed through a
NuPAGE 4 to 12 % Bis-Tris sodium dodecyl sulfate-
polyacrylamide gel (Invitrogen) and subsequently electro-
blotted onto a Hybond-P filter (Amersham Bioscience).
Flow cytometry
Cells were detached with trypsin-EDTA. Single cell sus-
pension were fixed in 4 % paraformaldehyde in PBS and
permeabilazed with 0,5 % Triton X-100 in PBS on ice.
mAb FoxF1 3454 and R-phytoerythrin-labeled goat anti
rabbit secondary antibody were used. Dox-treated (i.e.
GFP-expressing) cells incubated with secondary antibody
only were used as controls for compensation of leakage
of GFP fluorescence into the FL2 channel used to detect
R-phytoerythrin fluorescence.
Immunofluorescence
Cells were fixed in 4 % paraformaldehyde in PBS,
permeabilized in 0,5 % Triton X-100 in PBS and blocked
in 20 % FCS in PBS. After incubation with primary anti-
body diluted in 5 % FCS in PBS, the cells were incubated
with TRITC-conjugated secondary antibody (Jackson
ImmunoResearch) diluted in 5 % FCS in PBS. Vecta-
Shield/VectaShield-DAPI (3:2) was used for mounting,
and the cells were viewed under a fluorescence equipped
Zeiss Axioplan2 Imaging microscope.
Results
LOX is upregulated following FoxF1 overexpression
In order to identify factors involved in EMT and inva-
siveness that are regulated by NFI-C2 and FoxF1, we
used Affymetrix microarray to analyse changes in gene
expression in the mouse mammary epithelial cell line
HC11, following overexpression of FoxF1 or a stable form
of NFI-C2 (NFI-C2S, [3]). Several genes involved in EMT
were found to be oppositely regulated by NFI-C2 and
FoxF1, in line with our previous observations (Additional
file 2: Table S1 and Additional file 3: Figure S1) [3]. With
the purpose to narrow down the set of genes negatively
regulated by NFI-C2 and positively regulated by FoxF1, we
associated this microarray with a former microarray where
we used the MDA-MB 436 breast cancer cell line, a
mesenchymal-like cell line with high expression of FoxF1.
Fig. 1 LOX expression is upregulated by FoxF1 and repressed by
NFI-C2. a, RT-PCR analysis of FoxF1 (left panel) and LOX (right panel)
mRNA levels in parental, NFI-C2- or FoxF1-overexpressing HC11 cells.
b, RT-PCR analysis of FoxF1 (left panel) and LOX (right panel) mRNA
levels in MDA-MB 436 cells expressing empty vector or NFI-C2
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In that array we compared the transcriptome of MDA-MB
436 overexpressing NFI-C2S with that of vector control
cells [3]. This association showed that 45 genes were
downregulated 1.5 fold or more by NFI-C2 in HC11 cells
and MDA-MB 436 cells. Of these 45 genes, 17 were up-
regulated 1.5 fold or more by FoxF1 in HC11 cells
(Table 1). All of these 17 genes have been implicated in
tumorigenesis, especially in the process of EMT and inva-
sion. Also, many of these genes are involved in TGF-β sig-
naling (Abcg2, F2r, Fn1, Ltbp1, Lox, Nrp1, Pdgfc, Thbs1,
Tgfb2 and Vim). Among these 17 genes, the one that was
far most upregulated by FoxF1 was LOX. We used real-
time PCR (RT-PCR) to confirm, in both cell lines, that
NFI-C2 diminishes LOX expression and that high expres-
sion of FoxF1 is concomitant with high expression of LOX
(Fig. 1a and b). Given the parallels between LOX and
TGF-β involvement in EMT and invasiveness [22] we
wanted to investigate the effects of LOX upregulation fol-
lowing FoxF1 overexpression and what signaling pathways
are affected by FoxF1. TGF-β treatment of HC11 cells
resulted in an increase in FoxF1 expression (Additional
file 4: Figure S2A), confirming a coupling of FoxF1 to
TGF-β signaling. In addition, the expression of LOX
was also increased by TGF-β treatment (Additional file 4:
Figure S2A). However, in order to distinguish the effects
of FoxF1 from other pathways stimulated by TGF-β, we
chose to limit our further investigations in this study to
events downstream of FoxF1 expression.
Upregulation of LOX expression is an early effect of
FoxF1 expression
In order to discriminate between the direct and indirect
effects of FoxF1 we wanted to generate an inducible sys-
tem for ectopic expression of FoxF1. The non-malignant
human mammary epithelial cell line HB2 [23] was used
for this purpose. These cells do not have endogenous
expression of FoxF1. HB2 cells harbouring the tetracyc-
line repressor [24] were stably transfected with the
pcDNA3.1neo/TO/FoxF1-IRES-GFP plasmid. Using this
system, bicistronic expression of FoxF1 and GFP can be in-
duced by addition of tetracycline or its analogue doxycyc-
line (dox). Clone TFoxF1-50 with moderate expression of
FoxF1 was used for further studies (Fig. 2a and b). Induc-
tion of FoxF1 expression for 24 h resulted in morphological
changes; the cells became elongated with protrusions, par-
tial cell-cell-dissociation and remodeling of the cytoskeleton
into stress fibers were observed. After 48 h, cells appeared
fibroblast-like in shape (Fig. 2c). These observations are
consistent with the effect of FoxF1 on morphology in
HC11 cells (Fig. 2d). Furthermore, 24 h after induction of
FoxF1 expression, the LOX expression was increased
(Fig. 2e). This demonstrates that upregulation of LOX ex-
pression is an early effect of FoxF1 action, rather than a
consequence of malignant transformation seen after consti-
tutively overexpressing FoxF1 in HC11 cells [3]. It can also
be mentioned that TGF-β treatment of HC11 wild type
cells had effect on morphology, stress fiber formation and
Table 1 Affymetrix microarray data of genes downregulated by NFI-C2 and upregulated by FoxF1
Gene description Gene symbol Cancer association Reference
ATP-binding cassette, sub-family G (WHITE), member 2 Abcg2/Bcrp Multi-drug resistance [41, 42]
Coagulation factor II (thrombin) receptor F2r/Par1 Migration, invasion [43]
Epithelial mitogen Epgn Proliferation, migration [44, 45]
Fibronectin 1 Fn1 EMT [46, 47]
GLI pathogenesis-related 2 Glipr2 EMT [48]
Latent transforming growth factor beta binding protein 1 Ltbp1 EMT, invasion [49, 50]
Lysyl oxidase Lox Migration, invasion [17, 20]
Neurophilin 1 Nrp1 Migration, invasion, angiogenesis [51, 52]
Platelet-derived growth factor, C polypeptid Pdgfc Angiogenesis, invasion [53, 54]
Protease, serine, 23 Prss23 Proliferation [55]
Rho GTPase activating protein 29 Arhgap29 Migration [56]
Single stranded DNA binding protein 4 Ssbp4 Genomic stability [57]
Thrombospondin Thbs1 Invasion [58, 59]
Transforming growth factor, beta 2 Tgfb2 EMT, invasion [60]
WAS/WASL interacting protein family, member 1 Wipf1 Migration, invasion [61, 62]
Vestigial like 3 (Drosophila) Vgll3 Proliferation, migration [63]
Vimentin Vim EMT [64]
Affymetrix microarrays were used to compare the transcriptome of HC11 wild type cells to that of cells overexpressing NFI-C2 or FoxF1. Associating this array with
a previous array where the transcriptome of MDA-MB 436 cells overexpressing NFI-C2 or vector control, resulted in 17 genes downregulated by NFI-C2 in both
arrays and upregulated by FoxF1 in the HC11 array
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Fig. 2 (See legend on next page.)
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an increase in LOX mRNA levels (Additional file 4:
Figure S2A and B), which strengthen a possible coup-
ling of FoxF1 and TGF-β signaling.
FoxF1 overexpression increases invasiveness in a
LOX-dependent manner
It has been demonstrated that the secreted, catalytically
active 32 kDa form of LOX is involved in invasion [17].
High levels of secreted 32 kDa LOX could be detected
in culture media from FoxF1-overexpressing HC11 cells
(HC11FoxF1) but not in HC11 wild type cells (Fig. 3a).
Because LOX has previously been shown to promote
motility/migration, we used an in vitro invasion assay to
examine if the invasive phenotype observed in FoxF1
overexpressing cells compared to wild type cells (Fig. 3a)
was dependent on LOX activity. Treatment with the ir-
reversible LOX inhibitor β-aminopropionitrile (βAPN) sig-
nificantly decreased the invasion capacity of HC11FoxF1
cells (Fig. 3a). βAPN inhibits the activity of both LOX and
LOXL family members. To confirm the specific involve-
ment of LOX, we performed RNAi against LOX in
HC11FoxF1 cells. This treatment, which substantially
(See figure on previous page.)
Fig. 2 Induced expression of FoxF1 causes remodeling of the cytoskeleton and increase of LOX expression. a-b, FoxF1 and GFP expression in HB2 cells
expressing the tetracycline repressor plus the FoxF1-IRES-GFP construct (TFoxF1-50) analyzed by flow cytometry (a) and immunofluorescence
(b), 2 days after addition of dox (1 μg/mL) as indicated. c, photomicrographs and fluorescence photomicrographs of TFoxF1-50 cells,
untreated or treated with dox for 24 or 48 h, F-actin is stained with phalloidin-Alexa Fluor-546. d, photomicrographs and F-actin fluorescence
photomicrographs of parental and FoxF1 overexpressing HC11 cells, stained with phalloidin-Alexa Fluor-546. e, RT-PCR analysis of LOX mRNA
levels in TFoxF1-50 cells and TR34 control cells (HB2 cells expressing the tetracycline repressor), untreated or dox-treated for 48 h. b-d, Scale
bar: 20 μm
Fig. 3 FoxF1-induced upregulation and secretion of LOX increases invasiveness. a, left panel, western blot analysis of supernatant (culture media
(CM)) was concentrated 5X using Centrifugal Filter Units (Ultracel-3 K), Millipore) from cultures of parental and FoxF1-overexpressing HC11 cells
using LOX antibody. This antibody also detects a non-specific band at 70 kDa, which is used as loading control (LC). The middle panel shows
relative invasion capacity of HC11 wild type cells and HC11FoxF1 cells and the right panel the relative invasion capacity of HC11FoxF1 cells with
or without βAPN treatment (200 μM) for 48 h. b, left panel, western blot analysis of supernatants from cultures of HC11FoxF1 cells using LOX
antibody after transfection with LOX siRNA (+) or mock-treatment (−). Middle panel shows densitometry. Right panel shows relative invasion
capacity of HC11FoxF1 cells following LOX RNAi
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decreased LOX levels in the culture media, abrogated
the invasive ability of the cells (Fig. 3b and Additional
file 1: Figure S3). These data indicate that the increase
in LOX expression is responsible for the invasive
phenotype of HC11FoxF1 cells.
FoxF1 activates focal adhesion kinase
LOX has been shown to modulate the activity of focal
adhesion kinase (FAK) [19, 20]. Hydrogen peroxide is
produced as a byproduct of LOX catalytic activity and
can activate the Src/FAK signaling pathway, leading to
an increase in adhesion and cell migration [16, 25]. We
wanted to investigate if this signaling pathway is activated
in response to FoxF1. Indeed, FoxF1 overexpression in
HC11 cells resulted in phosphorylation of FAK at Tyr576
(Fig. 4a). This phosphorylation was decreased by treatment
with the LOX inhibitor βAPN or by decomposition of
hydrogen peroxide by catalase treatment. In TFoxF1-50
cells, an increase in FAK phosphorylation at Tyr576 was
observed after induction of FoxF1 for 24 h (Fig. 4b),
demonstrating an early FoxF1-induced FAK activation.
FoxF1 suppresses Smad2 activity and activate p38
signaling
In the Affymetrix microarray analysis comparing the
transcriptome of HC11 wild type cells to that of cells
overexpressing either NFI-C2 or FoxF1, we observed
many TGF-β related genes involved in tumorigenesis that
were upregulated by FoxF1 (Table 1). This prompted us to
investigate whether TGF-β signaling pathways are affected
by FoxF1. The oncogenic activity of TGF-β is suggested to
be a result of imbalance between canonical (Smad2/3) and
non-canonical (non-Smad), TGF-β signaling [26]. The
non-Smad pathways include various branches of MAP
kinase pathways, e.g. p38 MAPK. The nuclear levels of
phosphorylated Smad2/3 are reduced in high-grade
tumors [27], and the nuclear levels of phosphorylated
p38 are elevated in aggressive breast cancer [28]. In
HC11FoxF1 cells, the amounts of phosphorylated Smad2
in the nucleus, and total Smad2/3 in whole cell extracts,
were reduced, whilst the levels of phosphorylated p38 in
the nucleus were elevated, compared to wild type HC11
cells (Fig. 5a). Similarly, after induction of FoxF1 expres-
sion in TFoxF1-50 cells phosphorylated Smad2 and total
Smad2/3 levels were reduced. However, nuclear phosphor-
ylated p38 was barely detectable (Fig. 5b). p130Cas func-
tions as a scaffold molecule in focal adhesion complexes.
p130Cas is overexpressed in a variety of cancers. In breast
tumors, high expression of p130Cas correlate with poor
prognosis [29]. It has been demonstrated that p130Cas
reduces Smad2/3 activity and is involved in the regulation
of the balance between canonical and non-canonical
TGF-β signaling [30, 31]. HC11FoxF1 cells showed an
increase in the levels of phosphorylated as well as total
p130Cas compared to wild type HC11 cells (Fig. 5c).
In TFoxF1-50 cells, a modest increase of phosphory-
lated p130Cas and total p130Cas were observed upon
induction of FoxF1 expression (Fig. 5d). Taken together,
these findings show that FoxF1 reduces Smad2/3 activity
Fig. 4 FoxF1 activation of FAK is dependent on LOX catalytic activity.
a, upper panel, western blot analysis of whole cell extracts (WCE) from
parental and FoxF1 overexpressing HC11 cells, untreated or treated
with 200 μM βAPN or 200 U/mL catalase for 48 h, probed with
phosphospecific antibody FAK-pY576, stripped and re-probed with
FAK- and α-tubulin antibodies. Lower panel shows densitometry.
b, Western blot analysis of whole cell extracts from TFoxF1-50 cells
untreated or dox-treated for 24 h, probed as in (a)
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and upregulates p130Cas. Moreover, as a consequence of
FoxF1-promoted malignant transformation in HC11FoxF1
cells the p38 MAPK signaling pathway is activated.
Lysyl oxidase activation of FAK suppresses Smad2 signaling
Next we wanted to investigate if LOX is involved in the
signaling events regulated by FoxF1. Depletion of LOX
expression by RNAi in HC11FoxF1 cells led to a decrease
in phosphorylated FAK, whereas the levels of nuclear
phosphorylated Smad2, as well as total Smad2/3, were in-
creased following LOX depletion (Fig. 6a). As shown in
Fig 6b, the levels of nuclear phosphorylated p38 remained
unchanged, as did that of p130Cas, although, a small
increase in phosphorylated p130Cas was observed.
Fig. 5 FoxF1 represses Smad2 activity. a, upper panel, western blot analysis of nuclear extracts (NE) from HC11 and HC11FoxF1 cells probed with
phosphospecific Smad2 and p38 antibodies, stripped and reprobed with HDAC-1 antibody. Total levels of Smad2/3 and p38 were analyzed in
whole cell extracts (WCE). b, upper panel, western blot analysis of nuclear extracts from TFoxF1-50 cells, untreated or dox-treated for 24 h, probed
as in (a). c, upper panel, western blot analysis of whole cell extracts from HC11 and HC11FoxF1 cells probed with phosphospecific p130Cas antibody,
stripped and re-probed with p130Cas and α-tubulin antibodies. d, upper panel, western blot analysis of whole cell extracts from TFoxF1-50
cells untreated or dox-treated for 24 h, probed as in (c). a-d, lower panels show densitometry
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Treatment of HC11FoxF1 cells with FAK inhibitor in-
creased the phosphorylation of Smad2. The amount of
total Smad2/3 was not affected by inhibition of FAK, nor
the amount of p130Cas. However, phosphorylation of
p130Cas increased (Fig. 6c). These data indicate that
LOX-induced activation of FAK leads to suppression of
Smad2/3 signaling whereas the FoxF1-induced activation
of p38 signaling is independent of LOX. Furthermore, our
data suggest that suppression of Smad2/3 downstream of
LOX is not mediated by p130Cas. Instead, p130Cas
Fig. 6 FoxF1 represses Smad2 by a LOX- and FAK-dependent mechanism. a-b, upper panels, western blot analysis of HC11FoxF1 cells, mock-treated or
transfected with LOX siRNA. Supernatants of cultures (CM) were probed with LOX antibody, whole cell extracts (WCE) were probed with phosphospecific
antibody FAK-pY576 and α-tubulin antibodies, stripped and re-probed with FAK antibody. Nuclear extracts (NE) were probed with phosphospecific Smad2
antibody, stripped and re-probed with HDAC-1 antibody. Total levels of Smad2/3 were analyzed in whole cell extracts (a). Nuclear extracts were probed
with phosphospecific p38 and HDAC-1 antibodies. Whole cell extracts were probed with phosphospecific p130Cas and p38 antibodies, stripped and
re-probed with p130Cas and α-tubulin antibodies (b). c, upper panel, western blot analysis of HC11FoxF1 cells untreated or treated with FAK inhibitor
(FAK inhibitor 14, Santa Cruz) 20 μM for 1 h. The effect of the FAK inhibitor was confirmed by analyzing FAK phosphorylation levels at Y396 (data not
shown). Whole cell extracts were probed with FAK-pY576 antibody, stripped and re-probed FAK and α-tubulin antibodies. Nuclear extracts were probed
with phosphospecific Smad2 and HDAC-1 antibodies. Whole cell extracts were probed with phosphospecific p130Cas and Smad2/3 antibodies, stripped
and re-probed with p130Cas and α-tubulin antibodies. d, upper panel, western blot analysis of HC11FoxF1 cells mock-treated or transfected with p130Cas
siRNA. Nuclear extracts were probed with phosphospecific p38 antibody, washed, blocked and re-probed with HDAC-1 antibody. Whole cell extracts were
probed with p130Cas and p38 antibodies, washed, blocked and re-probed with α-tubulin antibody. a-d, lower panels show densitometry. e, summary of
signaling events regulated by FoxF1
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appears to be involved in the regulation of p38, as deple-
tion of p130Cas by RNAi treatment resulted in a de-
crease in nuclear phosphorylated p38 (Fig. 6d).
Discussion
Invasion and metastasis are the most fatal aspects of
cancer and can be facilitated by proteins that stimulate
tumor cell attachment to the extracellular matrix and
tumor cell motility.
Recently, it has become evident that LOX is involved
in increased malignancy and invasiveness in a variety of
human cancers. LOX is upregulated in invasive breast
cancer cell lines and breast carcinomas [32, 33] and has
been shown to facilitate breast cancer cell migration by
regulating cell-extracellular matrix adhesion formation
[16]. It has been demonstrated that LOX is a metastasis
promoting gene as it is important for tumor progression
to metastasis but not for tumor formation [20]. In this
study, we found LOX to be downregulated by NFI-C2
and upregulated by FoxF1. The increased invasion cap-
acity of cells overexpressing FoxF1 could be reduced by
inhibiting LOX activity or LOX expression. FoxF1 is
highly expressed in invasive breast cancer cell lines com-
pared to less invasive ones [3]. However, the levels of
FoxF1 in breast carcinomas have not been rigorously in-
vestigated due to the lack of specific antibodies. FoxF1 is
repressed by NFI-C2, which is lost during mammary
tumor progression and almost universally absent in
lymph node metastases [3]. Loss of NFI-C2 may be one
event that facilitates metastatic dissemination and upregu-
lation of factors like LOX. That FoxF1 upregulates LOX
leading to increased invasive capacity implicates FoxF1 as
a strong contributor to metastasis.
We show herein a signaling pathway where FoxF1-
induced upregulation of LOX activates FAK, leading to
suppression of Smad2 activity. Depletion of LOX dimin-
ished the activation of FAK and increased the phosphor-
ylation of Smad2 and the levels of Smad2/3. However,
inhibiting FAK only affected the activation of Smad2.
This indicates that activation of LOX disrupts a possible
scaffold function for Smad2/3 and that there are add-
itional factors other than FAK that are involved in the
regulation of Smad2/3 levels. Focal adhesions are multi-
molecular complexes consisting of a range of scaffold
and adaptor proteins. Elevated levels of the focal adhesion
scaffold molecule p130Cas have been shown to reduce the
activity of Smad2/3 [30, 31]. p130Cas was upregulated by
FoxF1 overexpression. However, suppression of Smad2/3
was not mediated by p130Cas in HC11 cells. Instead, our
data suggest that FoxF1 upregulates p130Cas in a separate
pathway, leading to activation of the p38 MAPK signaling
pathway. It is commonly known that p130Cas is a
downstream target of FAK [34]. Inhibiting FAK by
pharmacological treatment or LOX depletion increased
the phosphorylation of p130Cas, suggesting the presence
of an additional kinase that phosphorylates p130Cas when
FAK is inhibited. This indicates cross-talk between the
parallel pathways through which FoxF1 regulates Smad2/3
and p130Cas.
Upregulation of LOX, activation of FAK and subse-
quent suppression of Smad2 activation, as well as upreg-
ulation of p130Cas, were also observed in HB2 cells
following short induction of FoxF1 expression. However,
the p38 MAPK signaling pathway was not activated.
One explanation for this could be the differences in epi-
thelial characteristics between these cell types and a less
advanced transformation to malignant phenotype of
HB2 cells at that point. Long term expression of FoxF1
in HB2 cells was not possible owing to cell death after a
few days of induction. It was therefore not possible to
follow a potential FoxF1-induced EMT process in these
cells. However, a dramatic change in morphology was
observed, including formation of stress fibers and
fibroblast-like shape, typical features during progression
of EMT. When engineering inducible FoxF1-clones of
HB2 cells we observed a less pronounced phenotype
with a slower conversion to fibroblast-like morphology
in low-expressing clones and a lower degree of cell death
compared to high-expressing clones (data not shown).
These observations are in accordance with earlier studies
showing that FoxF1 effects are dose dependent [35].
Recent findings indicate that oncogenic TGF-β action,
which enhances tumor cell invasion and metastasis, is ini-
tiated by imbalance between canonical and non-canonical
TGF-β signaling systems. We present data indicating that
the association of FoxF1 with invasion and metastasis can
be a consequence of FoxF1 being involved in the regula-
tion of TGF-β signaling and promotion of non-canonical
TGF-β signaling: i) overexpression of FoxF1 affects the ex-
pression of many genes involved in TGF-β pathways; ii)
FoxF1 upregulates TGF-β2; iii) TGF-β treatment increases
FoxF1 expression; iv) FoxF1 expression suppresses Smad2
activity; v) constitutive overexpression of FoxF1 results in
activation of the p38 MAPK signaling pathway. Future
research will establish how FoxF1 is coupled to TGF-β
action, and whether these factors cooperate to influence
metastatic activity.
Imbalance between cell-matrix and cell-cell adhesions
is implicated in tumor progression. ECM remodeling
such as increased cross-linking of fibrillar ECM proteins
including collagen and fibronectin leads to matrix stiff-
ness, FAK activation and increased cell adhesion [19].
Changes in ECM density can trigger EMT via formation
of cell-matrix adhesions and disassembly of cell-cell
adhesions, altering intracellular signaling in a way that
enhances tumor cell migration and invasion [36]. FoxF1
downregulates cell-cell adhesion components, e.g. E-
cadherin and desmosomes (e.g. Dsc2, Pkp1, Dsg and
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Dsp), upregulates genes affecting cell-matrix adhesion,
e.g. LOX and fibronectin (Table 1 and Additional file 2:
Table S1), induces EMT [3] and invasiveness (Fig. 3).
Taken together, this suggests that FoxF1 contributes to
metastasis. In apparent contradiction to these results,
there are reports of FoxF1 acting as a tumor suppressor.
Lo et al. demonstrated that overexpression of FoxF1 in
breast cancer cells led to G1 arrest with or without
concomitant apoptosis, depending on cell type [37].
FoxF1 exerts dose dependent effects that are also reliant
on cell type, as discussed above. This can result in differ-
ences in the consequences of FoxF1 overexpression.
Tamura et al. have shown that p53-induced FoxF1 de-
creases the invasive capability of cancer cells [38]. FoxF1
may induce different effects depending on the tissue stud-
ied and on the cell- and signal-context with which FoxF1
is associated. The status of p53 could be a determinant of
FoxF1 action. This study relies on HC11 cells which ex-
press a mutant p53, and HB2 cells which are immortalized
with SV40 large T antigen leading to inactivation of Rb
and p53. FoxF1 is normally expressed in mesenchymal
cells [39, 40], which is difficult to reconcile with a tumor
suppressing function of FoxF1 in epithelial cells. Although
there are no reports of FoxF1 being involved in develop-
mental EMT, FoxF1 is expressed when EMT occurs dur-
ing gastrulation and in the sclerotome when cells migrate
to the notochord [7]. Clarifying the role of FoxF1 in
carcinogenesis would be of great importance in order
to evaluate the potential of FoxF1 as a molecular target
against breast cancer invasion and metastasis.
Conclusions
Our results show that FoxF1 increases invasiveness by
upregulating LOX and prompts a role for FoxF1 in the
regulation of the balance between canonical- and non-
canonical TGF-β signaling by suppression of Smad2/3.
These data adds new insights into the role of FoxF1 in
cancer and suggests that FoxF1 promotes metastasis.
Availability of supporting data
Microarray data are deposited in Gene expression Omnibus
(GEO). The MDA-MB 436 array is deposited with the
accession number GSE17636 and Doi: 10.1158/0008–
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the accession number GSE77551.
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Additional file 1: Figure S3. FoxF1-induced upregulation of LOX
increases invasiveness. An additional siRNA against LOX was used to
confirm the effect of LOX depletion on invasive capacity of HC11FoxF1
cells shown in Fig. 3b. A, densitometry of western blot analysis of
supernatant with LOX antibody after transfection with LOX siRNA or
mock-treatment. B, relative invasion capacity following LOX RNAi.
(PDF 286 kb)
Additional file 2: Table S1. Affymetrix microarray data of genes
involved in EMT, regulated by NFI-C2 and FoxF1. (PDF 48 kb)
Additional file 3: Figure S1. NFI-C2 and FoxF1 regulates expression of
genes involved in EMT. Reverse transcription PCR analysis of Desmoglein
1β, Twist1, Zeb1, Snail1 and GAPDH mRNA levesl in parental, NFI-C2- or
FoxF1-overexpressing HC11 cells. (PDF 475 kb)
Additional file 4: Figure S2. TGF-β upregulates FoxF1 and LOX, and
increase stress fiber formation. A, Real-time quantitative PCR analysis of
FoxF1 (left panel) and LOX (right panel) mRNA levels in HC11 wild type
cells after TGF-β treatment (5 ng/mL) for 48 h. B, photomicrographs and
F-actin fluorescence photomicrographs of HC11 wild type cells untreated
and after TGF-β treatment (5 ng/mL) for 48 h. Scale bar: 20 μm. (PDF 750 kb)
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